Fortress Biotech (NASDAQ:FBIO) posted its earnings results on Friday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.18, MarketWatch Earnings reports. Fortress Biotech had a negative return on equity of 71.96% and a negative net margin of 47.97%. The firm had revenue of $63.69 million for the quarter, compared to analyst estimates of $64.88 million.
Shares of Fortress Biotech stock traded up $0.01 during trading hours on Friday, reaching $1.10. 194,583 shares of the company’s stock were exchanged, compared to its average volume of 336,941. Fortress Biotech has a 52-week low of $0.83 and a 52-week high of $5.54. The firm has a market cap of $59.23 million, a PE ratio of -0.68 and a beta of 1.46. The company has a quick ratio of 2.76, a current ratio of 2.76 and a debt-to-equity ratio of 0.76.
A number of equities research analysts recently issued reports on FBIO shares. ValuEngine lowered Fortress Biotech from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. HC Wainwright set a $11.00 price target on Fortress Biotech and gave the stock a “buy” rating in a research note on Friday, August 10th. Finally, Zacks Investment Research raised Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $10.67.
WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2018/11/10/fortress-biotech-fbio-announces-earnings-results-beats-expectations-by-0-18-eps.html.
Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.